Skip to main content
SpringerLink
Log in

Challenges in the diagnosis and management of new-onset diabetes after transplantation

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

With the availability of newer and more potent immunosuppressive agents, post-transplant survival has markedly improved. However, these agents, together with the rising age of transplant recipients, have been associated with a rise in the incidence of new-onset diabetes after transplantation (NODAT). Besides the traditional risk factors for diabetes mellitus, such as age, obesity, hypertension, and family history of diabetes, additional risk factors for NODAT are identified. These include immunosuppressive therapy, hepatitis C infection, acute rejection, and deceased donor kidney transplant. In this article, we discuss the epidemiology, risk factors, pathophysiology, clinical course, and therapeutic and diagnostic challenges of this emerging disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jindal RM: Post-transplant diabetes mellitus—a review. Transplantation 1994, 58:1289–1298.

    PubMed  CAS  Google Scholar 

  2. Markell MS: Post-transplant diabetes: incidence, relationship to choice of immunosuppressive drugs, and treatment protocol. Adv Ren Replace Ther 2001, 8:64–69.

    Article  PubMed  CAS  Google Scholar 

  3. Davidson J, Wilkinson A, Dantal J, et al.: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003, 75:SS3-S24. In search of a new terminology that defines diabetes after transplantation attributable to immunosuppression, a consensus was reached during proceedings of an international expert panel meeting to rename diabetes after transplantation as "NODAT." The panel issued management guidelines that parallel those of type 2 diabetes.

    Article  PubMed  Google Scholar 

  4. Hariharan S, Johnson CP, Bresnahan BA, et al.: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342:605–612. Analyzed survival of kidney transplants using data from the Scientific Registry of Transplant Recipients of the United Network for Organ Sharing from 1988 to 1996. The projected half-life for grafts from living donors increased steadily from 12.7 to 21.6 years, and that for cadaveric grafts increased from 7.9 to 13.8 years.

    Article  PubMed  CAS  Google Scholar 

  5. Ojo AO, Hanson JA, Wolfe RA, et al.: Long-term survival in renal transplant recipients with graft function. Kidney Int 2000, 57:307–313.

    Article  PubMed  CAS  Google Scholar 

  6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.

  7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.

  8. Friedman EA, Shyh TP, Beyer MM, et al.: Posttranspalnt diabetes in kidney transplant recipients. Am J Nephrol 1985, 5:196–202.

    PubMed  CAS  Google Scholar 

  9. Fryer JP, Granger DK, Leventhal JR, et al.: Steroid-related complications in the cyclosporine era. Clin Transplant 1994, 8(3 Pt 1):224–229.

    PubMed  CAS  Google Scholar 

  10. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178–185.

    Article  PubMed  Google Scholar 

  11. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2002, 2(suppl_3):225.

    Google Scholar 

  12. Miles AM, Sumrani N, Horowitz R, et al.: Diabetes mellitus after renal transplantation: as deleterious as non-transplantassociated diabetes? Transplantation 1998, 65:380–384.

    Article  PubMed  CAS  Google Scholar 

  13. Montori VM, Basu A, Erwin PJ, et al.: Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25:583–592. This systematic review of the literature evaluated the reported incidence of NODAT. The 12-month cumulative incidence of new-onset diabetes in 12 studies of kidney transplantation ranged from 2% to 50%. Most cases of diabetes were diagnosed within 3 months after transplantation.

    Article  PubMed  Google Scholar 

  14. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583–595. This thorough review and meta-analysis evaluated the reported incidence of new-onset diabetes after solid organ transplantation in patients receiving calcineurin inhibitors. The incidence of new-onset diabetes was significantly higher among tacrolimus-treated patients, as compared with cyclosporine-treated patients.

    Article  PubMed  Google Scholar 

  15. Nam JH, Mun JI, Kim SI, et al.: Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001, 71:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  16. Hathaway DK, Tolley EA, Blakely ML, et al.: Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993, 7:330–338.

    PubMed  CAS  Google Scholar 

  17. Vesco L, Busson M, Bedrossian J, et al.: Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996, 61:1475–1478.

    Article  PubMed  CAS  Google Scholar 

  18. Sumrani NB, Delaney V, Ding Z, et al.: Diabetes mellitus after renal transplantation in the cyclosporine era—an analysis of risk factors. Transplantation 1991, 51:343–347.

    Article  PubMed  CAS  Google Scholar 

  19. Bloom RD, Rao V, Weng F, et al.: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002, 5:1374–1380.

    Article  Google Scholar 

  20. von Kiparski A, Frei D, Uhlschmid G, et al.: Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study. Nephrol Dial Transplant 1990, 5:220–225.

    Google Scholar 

  21. Mathew JT, Rao M, Job V, et al.: Post-transplant hyperglycaemia: a study of risk factors. Nephrol Dial Transplant 2003, 18:164–171.

    Article  PubMed  CAS  Google Scholar 

  22. Andrews RC, Walker BR: Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999, 96:513–523.

    Article  PubMed  CAS  Google Scholar 

  23. Wajngot A, Giacca A, Grill V, et al.: The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. Proc Natl Acad Sci U S A 1992, 89:6035–6039.

    Article  PubMed  CAS  Google Scholar 

  24. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H: Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997, 40:1439–1448.

    Article  PubMed  CAS  Google Scholar 

  25. Hollander AA, Hene RJ, Hermans J, et al.: Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997, 8:294–301.

    PubMed  CAS  Google Scholar 

  26. Hricik DE, Bartucci MR, Moir EJ, et al.: Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374–377.

    Article  PubMed  CAS  Google Scholar 

  27. Menegazzo LA, Ursich MJ, Fukui RT, et al.: Mechanism of the diabetogenic action of cyclosporin A. Horm Metab Res 1998, 30:663–667.

    Article  PubMed  CAS  Google Scholar 

  28. Tamura K, Fujimura T, Tsutsumi T, et al.: Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995, 59:1606–1613.

    PubMed  CAS  Google Scholar 

  29. Redmon JB, Olson LK, Armstrong MB, et al.: Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996, 98:2786–2793.

    Article  PubMed  CAS  Google Scholar 

  30. Oetjen E, Baun D, Beimesche S, et al.: Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 2003, 63:1289–1295.

    Article  PubMed  CAS  Google Scholar 

  31. Nielsen JH, Mandrup-Poulsen T, Nerup J: Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986, 35:1049–1052.

    Article  PubMed  CAS  Google Scholar 

  32. Duijnhoven EM, Boots JM, Christiaans MH, et al.: Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001, 12:583–588.

    PubMed  CAS  Google Scholar 

  33. Filler G, Neuschulz I, Vollmer I, et al.: Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000, 15:867–871.

    Article  PubMed  CAS  Google Scholar 

  34. Hjelmesaeth J, Hartmann A, Kofstad J, et al.: Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Medical Department B, National Hospital, University of Oslo, Norway. Transplantation 1997, 64:979–983.

    Article  PubMed  CAS  Google Scholar 

  35. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8–13.

    PubMed  CAS  Google Scholar 

  36. Fioretto P, Steffes MW, Sutherland DE, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.

    Article  PubMed  CAS  Google Scholar 

  37. Fernandez-Fresnedo G, Escallada R, de Francisco AL, et al.: Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc 2003, 35:700.

    Article  PubMed  CAS  Google Scholar 

  38. Salifu MO, Nicastri AD, Markell MS, et al.: Allograft diabetic nephropathy may progress to end-stage renal disease. Pediatr Transplant 2004, 8:351–356.

    Article  PubMed  Google Scholar 

  39. Kasiske BL, Vazquez MA, Harmon WE, et al.: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000, 11(suppl_15):S1-S86.

    PubMed  Google Scholar 

  40. Grinyo JM, Cruzado JM: Steroid or calcineurin inhibitorsparing immunosuppressive protocols. Contrib Nephrol 2005, 146:30–42.

    PubMed  Google Scholar 

  41. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000, 11:1910–1917.

    PubMed  CAS  Google Scholar 

  42. Abouljoud MS, Kumar MS, Brayman KL, et al.: Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002, 16:168–172.

    Article  PubMed  Google Scholar 

  43. Diagnosis and Classification of Diabetes Mellitus [no authors listed]. Diabetes Care 2005, 28:S37–S42.

  44. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.

    Article  PubMed  CAS  Google Scholar 

  45. McFarlane SI, Farag A, Sowers J: Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovasc Drug Rev 2003, 21:105–118.

    Article  PubMed  CAS  Google Scholar 

  46. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SUNY Downstate Medical Center, Department of Medicine, Renal Fellowship Program, 450 Clarkson Avenue, Box 52, 11203, Brooklyn, NY, USA

    Moro O. Salifu MD, MPH

Authors
  1. Moro O. Salifu MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fasika Tedla MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Preethi V. Murty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Serhat Aytug MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samy I. McFarlane MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salifu, M.O., Tedla, F., Murty, P.V. et al. Challenges in the diagnosis and management of new-onset diabetes after transplantation. Curr Diab Rep 5, 194–199 (2005). https://doi.org/10.1007/s11892-005-0009-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-005-0009-0

Keywords

Search

Navigation